Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
One day for sure; just wish we had a better idea WHICH one!
For me, ADMP has been a mini-TMDI, both in scale (I have 4x as many Titan shares as ADMP) and in required patience, as I have only been in ADMP since early this year (vs. following Titan for over a decade and owning stock for the majority of that time).
Both can be infinitely frustrating if I think too much about them because we all know the potential for each of them, so we wait. And wait. But when THAT day comes for each of these... it will all have been worth it!
(You were up extra early today, huh?)
Message in reply to:
Tic Toc ADMP..One day..Tic Toc...eom
He also commented on the strength of the instruments - a nice mention given how Trixie and Vickie (our rumored competitors!) are focused on smaller, weaker instrumentation.
$6B sounds like a sweet dream but man, I really hope you are right about that!
Message in reply to:
MDT just spent $1.1 BILLION to acquire a company after what seemed like a long layoff and it wasn't TMDI. Not a problem b/c I believe RT is correct and we aren't going to see a BO near term as they probably enter into a equity agreement with MDT after the current agreement ends. MDT will have time to build back up the reserves so they have $6B to pay for TMDI:)
Rocko already found it!
Post 130780
Titan is hiring Executive Assistant/Brand Communications (from MDT, BTW...) while Vicarious is hiring Legal Strategists for their defense team. Party Planning is pending the results of all the lawsuits. It's nice to be invested in the company which can focus their hiring efforts on their own industry.
Message in reply to:
More patents for Titan while a company like vicarious is hiring people to be director of party planning and director of weekly lunch planning.
I also have some questions...
When Zimhi gets approved, will pps settle into the $4 range or run up to double digits? And when the Tempol trials have initial results publicized, which big pharma company will be the first to bid on a takeover of the company? And at that time, will a $25 per share acquisition offer be accepted or laughed off as being too low? I'm just asking questions here.
frequent1, another good post here; thank you for sharing it - further evidence that Titan will not be trying to commercialize the Enos system, therefore Medtronic most likely will be the folks who do commercialize it. With Folks like Mr. Brar and Mr. Genova on board, development and protection of new technologies is an obvious strength to the organization and beyond Enos, that strength might be best utilized by a big company like Medtronic to improve their corporate offerings by developing more novel technologies for their new owners!
Message in reply to:
Just something to consider. We went from building a system and commercializing it, to just building a system, to now just building technologies? What exactly is the end game here? FDA approval for enos and then a buy out or just crank out and license "technologies" in the lab? I dont really care. Been invested here for about 4 years. Never sold. Still in the red by many many many many thousands. I'm sure you would understand why I'm cautiously optimistic. Good luck to us all.
November 01, 2019 3:29pm EDT
TORONTO--(BUSINESS WIRE)-- Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery
January 27, 2020 8:28am EST
TORONTO--(BUSINESS WIRE)-- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery
June 04, 2020 7:30am EDT
TORONTO--(BUSINESS WIRE)-- Titan Medical Inc. (“Titan” or “Titan Medical”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of single-port robotic surgical technologies,
Smirza, nice find!
What I find funniest about this is that this was long before the reverse split... so that means $360/share now! Okay, gotta factor in some dilution, but...
If anyone wants to do a quick research and math exercise, find what the outstanding share count was at the time... I'm guessing around 300M shares pre-split, give or take. So $12/share (also pre-split) would have meant $3.6B buyout value way back then! Now that this market has heated up substantially, and add 7 years of inflation, etc. I think it is another point of validation for anyone who thinks we are in the $4-$5B range as a minimum,and possibly a fair amount more.
Message in reply to:
https://seekingalpha.com/instablog/1282351-steve-rosenman/3029695-titan-medical-titxf-will-be-acquired
Interesting!
That remains to be determined. But I'm hopeful for value added.
Message in reply to:
Has Mc been a value added force or has he over promised and under delivered ? Some would say he outright LIED !
In the message referenced below, all of the IF statements are skewed heavily to the negative side. I don't understand why one wouldn't present a well rounded supposition and also mention what happens IF something very positive happens. Someone recently put out a 5 Options post last week which included good and no-so-good possibilities, and then presented an opinion as to what the expectations were. The gamut of possibilities was represented fairly.
The referenced message below portends it "WILL plummet if there is no extended agreement with MDT". I apparently need to complete that post and say it WILL SKYROCKET if the given supposition proves false.
Message in reply to:
IF and I say IF MDT already got what they want/need from Titan - my suggestion is that Mc use this conference on 7/29 to get another decent chunk. I do not want them to be in a position where they are ever forced to raise under $1.
This WILL plummet if there is no extended agreement with MDT announced come later Sept. Place your betz
Sorry so late to the game with this reply, but just got approved for this one so I'm re-posting:
Frankestin, that looks like a good one! Talk about driving value!
If Vicarious patents are worth $275M each, then this one should be a billion plus all by itself! Good visualization is truly one of the key elements of robotic surgery and having this one nailed down is definitely SWEET! Visualization is one of those systems that we can't just let slip away from us! Protected IP on this is awesome.
Message in reply to:
Boom!
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=%22titan+medical%22&OS=%22titan+medical%22&RS=%22titan+medical%22
1 gigabit per second.
2,000,000 pixels
10 bit pixel intensity values read
800 millimeters
Frankestin, I posted earlier to thank you for your post about this wonderful patent, but since I can't see it, I'm guess you can't either, so I'll try again in simpler form... Thanks for posting that patent, which is awesome.
Message in reply to:
Boom!
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=%22titan+medical%22&OS=%22titan+medical%22&RS=%22titan+medical%22
1 gigabit per second.
2,000,000 pixels
10 bit pixel intensity values read
800 millimeters
Frankestin, that looks like a good one! Talk about driving value!
If Vicarious patents are worth $275M each, then this one should be a billion plus all by itself! Good visualization is truly one of the key elements of robotic surgery and having this one nailed down is definitely SWEET! Visualization is one of those systems that we can't just let FREEly ROLL away from us! Protected IP on this is awesome.
Message in reply to:
Boom!
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=%22titan+medical%22&OS=%22titan+medical%22&RS=%22titan+medical%22
1 gigabit per second.
2,000,000 pixels
10 bit pixel intensity values read
800 millimeters
In my somewhat regular communications with Titan, I received a reply yesterday which, among other things, confirms "our current cash is expected to last through 2022." My prior recollection was that funding for 2022 would be covered by current cash plus the MDT M4 cash infusion; I assume this is what was actually meant but as written, it says "current cash" not "current and anticipated cash."
When the words just Roll Free ly off the tongue or off one's keyboard, they may have unintentionally slipped slightly, but no biggie; I'm good with it as I understand it, and if the update is accurate, even better.
I still recommend folks here write to them to get your own questions answered! And SCOOP while you can; I know shares aren't FREE but the prices will probably only ROLL upward from here!
I think "To da moon!" is still a few months offs, but we probably have another day of pain tomorrow, then Monday and Tuesday are hangover recovery days to start the drive back up to $1.70 and beyond.
So if we tap into the $1.40s tomorrow, it's practically a FREE ROLL of the dice for scoopers, and likely the last time we test these chilly waters. Things heat up next week.
Message in reply to:
Good move, I think we test $1.49 and then it’s to da moon!
Third attempt at this one:
Hey Rocko, I liked your write-up this morning with the 5 possibilities listed and I agree that they are probably the 5 most likely scenarios. Possibly worth a sticky on that post!
As for the probability of each, I do see things a little differently than you. I think Option 3, equity stake, is a lower probability because Medtronic didn't like the way it worked out with Mazor and they have probably learned from that mistake.
Option 1, Titan going it alone is also highly unlikely in my opinion; they honestly don't have the resources to deploy such a complex product into a highly competitive market without bigger backing. The closest to this option would be if they sign a marketing agreement with another Big to utilize someones existing sales force and contact base, but another Big who would be interested would just buy them out, so I am doubtful on Option 1 as written.
Option 5, just keep licensing patents, I think is also unlikely because they would quickly alienate the entire market - every new licensee would be a poke in the eye to prior licensees and the market would rather abandon them completely than risk competing with 5 other companies all using the same tech.
Option 4, another Big steps in with an offer, is a real possibility and my pick for second most likely option. I might have ranked it lower if I hadn't been told by Titan Mgt that the Medtronic rep has been specifically excluded from some board meetings; I think other suitors are most likely the topic of discussion at those boar meetings and hence I believe this one is firmly on the table.
Absolute greatest likelihood in my mind is Option 2, immediate buyout by Medtronic or at least an attempt by them to do so. Titan may already have other contacts in place who are working on counter-bids; some offers have non-compete clauses stating Titan cannot then shop for other offers, but as I stated, my belief is that the shopping started a while back. Either way, MDT won't want to drag their feet on a deal because of how it worked out with Mazor. And another hitch with Mazor was system reliability - so there's a good chance that the handshake deal with Mr. Martha includes the additional tweaks Titan has been doing over the past year, possibly at Geoff's request, so they know that what they are getting will hit the ground running - since everyone wants an explanation of why we still seem to be refining our platform. I'd go so far as to guess that the whole Enos/endoluminal capability was driven by this handshake deal, maybe even before Mr. Martha took the helm. The $18M milestone/raise might have been to meet funding requirements for this MDT-requested development effort (explaining why Titan's raise was one of the Medtronic milestones). That money funded development to meet MDT's development vision but wasn't provided by Medtronic directly because... Mazor all over again if they did. And conveniently, it was all pre-arranged so it could be announced a day or two later! When is the last time before that Titan announced a raise and then wrapped it up that fast? Never. It was a done deal.
All my opinion, of course, as always... but yeah, I'm sticking with Option 2 and now you all know why. And if my reasoning here also answers some questions or doubts that were lingering in the back of your mind... you're welcome!
Message in reply to:
Obviously the daily back and forth is really pointless but imagine if we vented our frustration with this stock to people we know - probably wouldn't end well. So I started thinking about Milestone 4. Milestone 4 is due at the end of Sept. So b/t now and Sept 4th, there will be daily back and forth and its all just background noise. Shorters will back their positions and longs will posit for theirs with no impact either way.
So back to Milestone 4. One thing that we can agree on is that if Milestone 4 is not delivered (the prototype) then its a problem (and makes option 5 - not really an option). So when Milestone 4 is hit and Titan announces it and receives payment what are the next options.
Option 1. Titan receives money, pays off loan and has a Single Port Surgical robotic platform ready for Regulatory Submittal. They decide to go it alone.
Option 2. Medtronic buys out Titan immediately for one lump sum of money (its pretty clear that the BO range projections on this board have an extremely wide spread)
Option 3. Titan and Medtronic enter into another agreement (similar to Mazor deal) where Medtronic takes an equity stake and helps Titan thru human clinical trials, regulatory process and commercialization process.
Option 4. Another player comes in and makes an extremely attractive offer to buy ENOS, Entire Intellectual property portfolio and the world class R&D team.
Option 5. Titan decides to license IP and know how (consistent revenue stream)to other companies eager to get into Surgical robotic space, continues to crank out patents and still has a Single Port Surgical Robotic platform.
When prototype is delivered, I lean towards Option 3, it makes the most sense from both parties and the most logical. It will allow Medtronic to make the ultimate commitment to surgical robotics and Titan and deliver surgical robotic platforms that will be an alternative to ISRG and quite frankly a better platform. Also, acquiring the Single Port platform prevents another company from coming in and acquiring it(some argue the Medtronic can just develop a single port in house but Titan would be a prime competitor with no patent infringement - quite attractive to a JNJ, ISRG, CMR, Stryker, Olympus, etc).
Option 3 would allow Medtronic to collect all the clinical data and studies from ENOS to help in their upstream and downstream marketing. It would also allow them to get in early to help set up manufacturing, supply chain and logistics so when roll out happens its seamless (unlike the Mazor acquistion).
Option 3 would help them tremendously with the HUGO rollout b/c as they speak to CEOs and CIOs of health system, its quite an attractive package to talk about multi-port, single port and endoluminal ALONG with all of Medtronic's other business with their system/facilities.
Option 3 would allow them to move with speed thru the clinical and regulatory process b/c they would be sponsoring Titan and allow Titan to run point with assistance from Medtronic (especially b/c Medtronic will be coming off the heels of their own clinical trials across facilities where the road has been paved). Hospitals and clinicians would be familiar with the shared IP in the systems (i.e hand pieces, ergonomic physician station, etc)
I am hoping for Option 3 b/c I believe as a shareholder that is the best option for my return on investment. Options 1, 2, 4 and 5 all will lead to appreciation but maybe not at the rate of return Option 3 would.
It will be fascinating to say the least and I know every single person who comes on this board is wondering what Option will it be.
Mark this one on your calendars everyone! He said let's focus on Titan!
Message in reply to:
Let’s focus on Titan
How much money do you think Titan will need to raise before they see revenue from sales of enos?
Rocko, nice link. Shows they (Vicarious) actually have 5 approved patents, not just 4. And one was just approved at the end of last month. The first was approved in 2017. Let's see... 5 patents... 2017 to 2021 means an average of one per year. Most weeks this year Titan has gotten at least one, and often 2 new patents issued.
Is this not a reasonable measure of how competitive they are with Titan? The two biggest brags about Vicarious are that they hit up their wealthy friends for big $$, and their impressive technology - which is clearly represented by patents, the basis for converting tech to market share. Let's see again... who wins if thisnwas any type of game? 30 applications or over 170, nearly 6 times as many? 5 approved patents, or almost 90, nearly 18 times as many?
Anyone bragging about Vicarious can't be very good at math because my numbers here are real and verifiable. And I suggest people do their own verification and then see who they want to believe.
Message in reply to:
Here are all of vicarious patents - don’t even need to scroll down
https://patents.justia.com/assignee/vicarious-surgical-inc
Sure, Vicarious has big money and big names behind them... but Medtronic has big CREDIBILITY behind them, and THEY are working with TITAN. To the best of my knowledge, Geoff Martha is not in the middle of a messy multi-billion dollar divorce while trying to fight assertions that he spent a little too much time taking the Porsche out at lunch to nearby motels or flying around in Mr. Epstein's minor-laden jet. Mr. Martha has thus far maintained a highly respectable demeanor in his professional AND personal lives, and I believe his leadership will provide a much more stable basis for Titan's future than relying on Mr. Gates' rapidly dwindling credibility and reputation.
Ah, yes, Becton Dickinson... the world leader in Surgical Robotics! Credibility galore in the market space! Oh, wait... Must be someone else.
And who's bending over? No, this isn't the venue to discuss those minors on the jet plane.
Reputation means a lot. It might be a good time to stop name-dropping names that could find themselves in jail by this time next year.
Even Mr. McNally's reputation is actually, factually, quite solid. All doubts about his credibility and reputation are solely from this very message board, contributed by folks who have reasons to wish ill will against the company he is leading. But in reality, he has successfully led a couple medical device companies, one he sold outright to Moog and another which he merged with Omniguide. His history is all success. He even runs a non-profit charity with his wife, doesn't he? And if his biggest score has taken little more time than initially hoped, so be it. It should prove to be well worthwhile.
So the combination of Mr. McNally and Mr. Martha leading this project is top tier; both are of upstanding character and proven top level professional capabilities.
And it is much more on point for discussions on this board to be centered around these two gentlemen instead of vicarious, BD, and Bill Gates.
Message in reply to:
Vicarious has big time money behind them…
EQUITY investments from BD, Bill Gates and other high profile players…they have no need to bend over….
They took the OLD platform, known as SPORT, to these places, where it served its function and from that, with those lessons learned, the Enos platform has been created. Enos is a new, modern, mature platform, whereas by comparison SPORT is outdated, immature, and rudimentary; and now basically one can say SPORT is useless. Completely useless now and moving forward. Enos is the future; SPORT is an outmoded relic built on older technology (maybe even based on IREP, who knows?). SPORT isn't worth the 25 cents that a share cost back then!
Message in reply to:
They’ve taken the platform to NYC to show investors, 2 units to Boston to show to the robotic surgeons, units in Florida at the Nicholson Center, Columbia University in NYC and a unit in France….
All these years…..and years….and years
Medtronic got the milk…..
Years to go
GLTY
Also, can anyone explain what Titan's BOD was discussing during the board meetings (plural) where the Medtronic monitor was excluded? Most logical explanation is discussions were centered around other potential acquirers, and with enough merit to demand absence of the monitor. Or should we believe they were planning a surprise birthday party for Mr. Martha and didn't want him to know? My money is on other potential acquirers.
How on earth could MDT buy 35% of Titan for $70M? Open market? Anyone buying 50m shares will inherently drive the price up substantially while trying to accumulate so many shares. So $70m is impossible. And they would need to file with the SEC when their ownership percentage hits a number far below 35%. And if they filed that paperwork, everyone knows what is going on and the price would shoot up even faster than mere accumulation of 35% of the shares.
So again, how can MDT buy 35% of Titan for $70m? Hint: they can't.
Rocko, please don't forget to mention the following when talking about competition, especially in the single port realm:
"da Vinci Xi can perform single port surgery as well [61,97]. When da Vinci Xi is being used for single port surgery, only two of the three instrument arms are used. The instrument arms cross over in the trocar such that the right instrument arm controls the left end effector, and the left arm the right end effector [61]."
https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwi25p6isMTxAhVHVs0KHXfUBmw4FBAWegQIBRAD&url=https%3A%2F%2Fres.mdpi.com%2Fd_attachment%2Frobotics%2Frobotics-09-00042%2Farticle_deploy%2Frobotics-09-00042-v2.pdf&usg=AOvVaw3pnU-4hSfKv9_IyOm1r51J
The very unnatural manipulation of end effectors by surgeons using the current Xi SP system could well be a factor in suppressing SP sales to date, allowing for a competitor with a human-friendly user interface to step in and gain accolades and market share very quickly upon release to the market. I think Medtronic would like to be the supplier, considering (as you noted) that SP is already an $8B value with the only SP offering being crossed up. Imagine the potential market share of a system that surgeons WANT to use!
Message in reply to:
Titan is developing an endoluminal prototype w Titan IP in it.
Reminder for anyone not paying attention: in order for anyone to compete w ISRG they will need multi port, single port and endoluminal. So what does Medtronic have, they have a multi port system called Hugo, they will need an endoluminal system (we will call this milestone 4 prototype) and they will need a single port system (Enos)
Auris (endoluminal - one indication) went for $5.7B. The software science project vicarious w NO PATENT PROTECTION is a POS knock off single port system valued at $1.1B (btw it’s single indication is hernias). ISRG SP - single indication - has added over $8B in MC to ISRG.
IT is very easy to get to a multi billion dollar valuation w Titan considering they will deliver an endoluminal prototype w Titan IP, they have a next generation surgical robotic single port system, their IP will enhance second generation HUGO SYSTEM, they have a world class R&D team and one of the best IP portfolios in the surgical robotic space.
Sandoz??? Since when?
"This “Changes Being Effected” supplemental new drug application provides for labeling updates associated with the addition of Sandoz Incorporated (Sandoz Inc.) as the new distribution and commercialization partner. The labeling updates include a new color scheme for the carton and font, new NDC number, a new Set ID, and the addition of Sandoz Inc. as a distribution partner. The single-pack is also removed from the supplied options."
Okay, I discovered they had a previous relationship and they appeared to have parted ways last year. But this letter was part of the FDA approved package per the new announcement. So now I am slightly more confused than before!
https://www.msn.com/en-us/health/medical/where-do-coronavirus-variants-come-from/ar-AALA4ie?li=BBnb7Kz
A little more detail on where COVID variants arise from. This therefore begs the question of how much Tempol could benefit humanity by preventing these mutations. The variants could well re-present the biggest future threat we might face.
Let's get this Tempol train rolling!!!
Thanks for clarification, ORtrader... I assumed it was from our recent stint under $1. Not sure which reason I would have preferred!
Hey slimhere... I got your message but I'm not a paying member so I can't reply to you off line. I hope you see this.
As for not NASDAQ compliance, a convenient hypothesis could be that they are negotiating their acquisition so it just won't matter! Otherwise I would have expected them to be more sensitive to maintaining compliance. If you do contact IR and get a reply, please do share! If it sounds like a reasonable reason or maybe is already in the works, that's one thing... but if it sounds like BS or they say they just aren't interested in maintaining compliance, Roll might have provided the reason with the aforementioned hypothesis. Fingers crossed, anyway!
https://www.msn.com/en-us/health/medical/india-warns-of-new-versions-of-delta-variant-spreading/ar-AALrizl?li=BBnb7Kz
The need for Tempol is growing REALLY FAST!!!
This is a global market, a global issue, and for the sake of humanity, some powerhouse like JnJ should be looking at the quickest way to control this life-saving medication and distribute it as quickly and broadly as possible.
Acquisition is the most logical way to save thousands and possibly millions of lives.
Brave11, it is true that we MAY never know for sure who else, if anyone, they might be talking to about acquisition. However, Titan management did tell me that they have had more than one board meeting with the MDT monitor excluded. This can only happen if discussions were to either breach some attorney confidentiality, or if they were in conflict with the relationship between MDT and Titan. Talking about other potential suitors is clearly the latter. In either case, the exclusion of the monitor means they were talking about SOMETHING interesting.
Message in reply to:
Here’s the thing you don’t get or your agenda just won’t allow you to say it, we’ll NEVER know if anyone one else is kicking the tires on Titan. Thats NOT public information.
Roll, excellent synopsis for ADMP! Covered plenty of ground on this one!
Message in reply to:
Morning Folks....so where are we at with ADMP....
First off will say I am still an Ape.Small Ape,but an Ape.Why?Math and percentages on the $$$ going forward.Robots are great and Still in robots but once again.Math and percentages on your $$$.That said,being a tad spread out with the heaviest on ADMP.Math.Simple Math.
ADMP..Roll has been in this stock since FDA approval on Symjepi(approved type epipen we got FDA approval for in 2016 I think) followed by years later Symjepi Jr, lower dose for kids. So we have SR.and Jr..With a new partner last year late named USWORLDMED out of Kentucky.We split net profit with them 50/50 across the board for sales of our two products.They are incharge of marketing,shipping,collecting,contracts such as VA clinic,Walgreens,Kostco etc...Sales are estimated at 90% this first quarter when ADMP files(which is late filing currently)and is in non compliance with Nasdaq and has 180 days to file..A small issue imo,and could be a strategic move by ADMP as it cries broke for funding two upcoming trials we are doing.
1) For the early treatment of Covid symptoms using 2 capsules 800mg on 300 patients with interim peak at 60 patients a month later once trial 2/3 phase begins.The announcement of GOV full funding through NIH should be in excess of 15 million+ costs through EUA (emergency use authorization) for FDA approval so if Tempol is great we could use it this Fall.It is being fast tracked in the OWS(operation Warp Speed) program for all Covid19 companies battling the disease.This funding and study could be announced at any time going forward as the leg work has been underway through CRO(Contract Research Organization) which is basically a contractor that does the leg work getting a study or trial underway for companies that want to test a drug on humans.
Look up CRO USWORLDMED for these.Both are reputable companies.ADMP also is waiting on Full FDA Approval for it's Opioid Drug ZIMI which would be a strong drug used in a Symjepi dispenser like an epipen to save lives of those who have overdosed on something.FDA Approval can come anytime including today but has the standard PDUFA Date of Nov 12,2021.So what if it goes the distance,imo it won't as ADMP asked the FDA to expedite the approval as it has sought FDA approval two previous times but FDA heehawed around screwing over ADMP on dosing issues.The drug is FDA approved as well as Symjepi delivering system too.I know,I know,Why then no approval thus far?FDA running interference on behalf of Big Pharma.ADMP did not have to change a thing with this latest refiling for FDA approval on ZIMHI.
SO what,we have Tempol and the GOV funding/study to keep the stock moving up as well as perhaps record first quarter Earnings.We did an offering of 50 million shares or so in FEB 2021 and that was 1/2 our outstanding shares or 50 percent prior to the offering. ADMP has 44 million in cash and should receive up to 25 million a one time payment from USWORLDMED our partner upon approval from FDA for ZIMHI.Plus we are selling our USC-manufacturing Compound in Arkansas which is expected to close June or July per ADMP netting us another 10-20 million.
SO,ADMP does NOT Need Cash (At the moment) for the naysayers that brought this subject up last week.DO your dd on ADMP as Roll thinks this is a BO play as well as ADMP is undervalued,has a great pipeline and many other things to be talked about and additional phase 3 study for a Tempol Topical Gel...waiting to start soon too.ADMP said April CC video See website for replay- that funding for that should be covered as well from PA university.....
And NO ROLL isn't proofing this wind either ;0) IMO,ADMP is going places finally once and for all.It will be known by many going forward should Tempol be the greatest drug ever for treating early lung infections by a capsule for folks that caught Covid19.No pump here just the story as to where ADMP is currently at...........Now you know the rest of the story..RIP Paul Harvey..
Thanks Roll
So I decided to take SRC's advice and do a minute of research.
https://dictionary.law.com/Default.aspx?selected=631
Certainly we aren't talking about signing one's name on the back of a check with regard to providing a positive review of Tempol, so definition #1 of "endorse" is out. But...
2) the act of pledging or committing support to a program, proposal or candidate.
So until ADMP gets the check from the NIH, maybe "endorse" isn't quite the right term just yet.
But once ADMP gets to "endorse" a check from NIH for Tempol trials, I'd say it will be undeniable - despite the NIH's global disclaimer that they don't endorse anything. They aren't running around writing checks without having a pretty good reason to do so. Sending ADMP a check would constitute an "endorsement" according to the second definition.
“An oral drug that prevents SARS-CoV-2 from replicating would be an important tool for reducing the severity of the disease.”
This sounds to me like an endorsement, just not one which calls out Tempol specifically yet. The NIH info over the past couple weeks certainly indicates that Tempol appears to meet this criteria, so in combination, I think the word "endorse" is applicable. Bear in mind, the quote is from the NICHD, not the NIH directly, but NICHD does fall under the NIH umbrella.
Message in reply to:
Endorsed? This is simply not accurate and not the position the NIH took. Some of their words...
"may be a promising"
"we are hopeful"
"clinical studies are needed to determine if the drug is effective in patients, particularly early in the disease course when the virus begins to replicate"
Saying that the NIH "endorsed" is misleading!
https://www.msn.com/en-us/news/us/delta-variant%e2%80%8b-could-cause-next-covid-wave-this-virus-will-still-find-you/ar-AALjrWP?li=BBnb7Kz
When infection rates start to climb again, maybe there will be more pressure to get Tempol approved quickly. Maybe! Please?
I think it goes WAY beyond this in potential. This cut off Virus replication. Vaccination has long been known as the only real method to fight viral infection; antibiotics target bacterial infections, not viral. Viruses can have various medications to treat symptoms but only recently has anything been created to try to rein in the actual virus; it was typically allowed to run its course and just try to keep a patient as comfortable as possible. But if Tempol can prove effective in a broad spectrum or full spectrum of virus replication, think of the potential! As an example, HIV is a virus. As are Chickenpox, herpes, shingles, mumps, measles, etc. Is the future of Tempol so wide-ranging? Definitely possible, with trials an approvals for efficacy against each, since safety is already proven.
NOW what should this stock be worth??
Message in reply to:
If interim is stellar,Tempol could get used for many strains maybe....
but what I see down the road..better than Covid use,is decades of use with an extended label for the ordinary FLU or Cold..Think about that for a second..Tic Toc..lungs are lungs if the safety is there and it is used to clear lungs from infection..Much still in the air of course..
Thanks Roll
I'm guessing that if we can find an article saying Tempol is effective against the Delta variant, we run up nicely! Delta seems to have folks scared again already. And based on its functional mechanism of inhibiting the RNA replicase, it should work just as well against Delta as it does against the more common (so far) strains.
I'm new to the ADMP board here, but been on iHub too long!
Anyway, I upped my ADMP position to 40K shares a week or so ago; I figure I might as well keep an eye on things over here as well! A little more info, or at least further affirmation of my suspicions as to where this is going, is a good thing!
Livendi, I was also focused on maximizing my share count by trying to time my last big purchase on a dip.
A friend of mine convinced me that it just isn't worth the risk. Anything could happen at any time, from buyout to equity stake to... who knows. Something could drive our price up faster than expected, and I lose out on a few hundred shares or a couple thousand extra shares. Small potatoes in the grand scheme of things. Or the buyout could catch us all by surprise while I was waiting to use my money to get the extra couple hundred shares. Then I miss out on scooping my last 30k shares because I wanted 30,100. That would be risky and foolish. So I'm getting as much as I can, as soon as I can. Monday, actually.
Milestones? Nothing can be said for sure either way so I can't rely on a buyout announcement based on that. And knowing they've had board meetings in the past year without MDT allowed to monitor, I don’t want to accept that risk.
Just to provide some clarifications...
According to another poster, one third of 165 is 12. 12 patents were licensed, which is one third of Titan's patent portfolio. So 12 is one third of 165, if you believe their math.
Also, nobody else has any interest in this technology. So the multiple board meetings which were held by Titan while excluding the Medtronic monitor from those meetings were for... I dunno. If it wasn't to discuss other possible "partners" then I just don't know what they were talking about. Butnthats just me, I apparently have no imagination.
As I keep encouraging others to ask Titan questions. I asked about board meetings which were held with MDT representation excluded. There were more than one such board meeting. Why? Go ahead Honeycomb and answer that one. What were they talking about? Looking at the requirements for Titan to exclude MDT, it was something that either violated attorney confidentiality or was a conflict of interest between the two organizations. They wouldn't tell me why MDT was excluded but it happened more than once. Please explain!
And as always, feel free to confirm for yourself. I will continue to request people get their own info instead of believing all the misinformation offered here by others.
DiceMaker, this is a great post! I'm mostly replying to it in order to ensure it doesn't slip past too many people.
I especially love the last line!
(With thanks also to ORNurse for helping bring the topic to our attention!)
Message in reply to:
Your last sentence reminded me that the loan agreement does allow Titan to exclude Medtronic from that type of meeting. Just posting for everyone’s reference.
“Borrower may, by giving prior or concurrent written notice to Lender, exclude the Lender Designee from attending any meeting of the board of directors and its committees, or relevant portion thereof, and/or from receiving any such notices, information and other materials provided to Borrower’s directors and committee members (as applicable), if and to the extent that, in the reasonable opinion of Borrower and Borrower’s counsel (i) such attendance or receipt of such information or materials would jeopardize or infringe any attorney-client privilege, attorney work product or other similar privilege or protection belonging to Borrower, (ii) the topic of such meeting or content of such information or materials (or, in each case, relevant portion thereof) relates to a matter in which the interests of Lender and Borrower are in conflict with each other”
Sure. Let's just go with that because according to HC7s, everything Mr. McNally ever said is a lie, and you don't seem to trust him much more that HC does.
But... what if Mr. McNally told me they have no PPS catalysts for this summer? Would you guys believe him if he gave bad news?
Message in reply to:
We can all take that as “there are NO catalysts to a PPS increase this summer” LOL.
BelizeMe